Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04745351 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19)
A Phase 3 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 3
- Development phase
- 249
- Enrollment target
NCT04745351 is a Phase 3 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 249 participants.
The verdict
NCT04745351, a Phase 3 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 249 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate whether remdesivir (RDV, GS-5734™) reduces the composite risk of death or invasive mechanical ventilation (IMV) through Day 29 in participants with severely reduced kidney function who are hospitalized for coronavirus disease 2019 (COVID-19).
Interventions
- DRUG Standard of Care
- DRUG Remdesivir
- DRUG RDV Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 249 participants |
| Start Date | 2021-03-31 |
| Est. Completion | 2022-05-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04745351
The ClinicalTrials.gov registry entry for NCT04745351 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 249 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Standard of Care is the first listed.
NCT04745351 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04745351 about?
NCT04745351 is a clinical study titled "Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19)". The primary objective of this study is to evaluate whether remdesivir (RDV, GS-5734™) reduces the composite risk of death or invasive mechanical ventilation (IMV) through Day 29 in participants with severely reduced kidney function who are hospitalized for coronavirus disease 2019 (COVID-19).
What is the current status of trial NCT04745351?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 249 participants. The study started on 2021-03-31. Estimated completion is 2022-05-24.
What interventions are being tested in trial NCT04745351?
The interventions under investigation include: Standard of Care (DRUG), Remdesivir (DRUG), RDV Placebo (DRUG).
Who is sponsoring clinical trial NCT04745351?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.